H1N1 Influenza (Nursing)

Review questions:
Take Free Questions on this Article

Learning Outcome

  1. Recall the presentation of swine flu
  2. Describe the treatment of swine flu
  3. Summarize the nursing management of swine flu

Introduction

H1N1 Swine flu is a subtype of influenza A virus (a communicable viral disease), which causes upper, and potentially, lower respiratory tract infections in the host it infects, resulting in symptoms such as nasal secretions, chills, fever, decreased appetite, and possibly lower respiratory tract disease. H1N1 swine influenza is a common infection in pigs worldwide, and that is why it is also known as swine flu. H1N1 swine flu leads to respiratory disease that can potentially infect the respiratory tract of pigs. Sometimes, people who are closely associated with pigs or in the proximity of pigs have developed swine flu (zoonotic swine flu). Swine influenza viruses can potentially cause infections in humans if antigenic characteristics of the virus change through reassortment. When this happens, transmission from person-to-person is usually inefficient. Influenza A pandemics such as the ones in 1918 and 2009 can occur if the transmission from person-to-person becomes efficient. [1]

In 1918, a deadly influenza pandemic caused by H1N1 influenza virus, also known as the Spanish flu, infected approximately 500 million people around the world and resulted in the deaths of 50 to 100 million people (3% to 5% of the world population) worldwide, distinguishing it as one of the most deadly pandemics in human history. In 2009, a new strain H1N1 swine flu spread fast around the world among humans, and the World Health Organization (WHO) labeled it a pandemic. However, the 2009 H1N1 virus was not zoonotic swine flu because it was not transferred from pigs to humans. Instead, it spread through airborne droplets from human to human, and potentially, through human contact with inanimate objects contaminated with the virus and transferred to the eyes or nose. This virus caused similar symptoms to those seen in swine, possibly due to reassortment of the viral RNA structure, which allowed human-to-human transfer. [2][3]

Despite the name, an individual cannot acquire swine flu from eating pig products such as bacon, ham, and other pig products. 

Nursing Diagnosis

  • Fever
  • Cough
  • Muscle aches
  • Sore throat
  • No appetite
  • Chills, malaise
  • Headache
  • Vomiting

Causes

H1N1 influenza virus is an orthomyxovirus and produces virions that are 80 to 120 nm in diameter, with an RNA genome size of approximately 13.5 kb. The swine influenza genome has 8 different regions which are segmented and encode 11 different proteins:

  • Envelope proteins hemagglutinin (HA) and neuraminidase (NA)
  • Viral RNA polymerases which include PB2, PB1, PB1-F2, PA, and PB
  • Matrix proteins M1 and M2
  • Nonstructural proteins NS1 and NS2 (NEP), which are crucial for efficient pathogenesis and viral replication

The surface glycoproteins HA and NA are how the H1N1-strain is differentiated from other strains of influenza A (H1N1, H1N2) depending on the type of HA or NA antigens expressed with metabolic synergy. The function of hemagglutinin is to cause red blood cells to cluster together, and it attaches the virus to the infected cell. Neuraminidase helps move the virus particles through the infected cell and assists in budding from host cells.

The H1N1 swine influenza viruses can potentially cause infections in humans if antigenic characteristics of the virus change. In 2009, the pandemic which started in Mexico with the H1N1 strain displayed a combination of segments of 4 different influenza viruses (quadruple genetic reassortment): pig-origin flu north American avian (comprising 34.4%), bird-origin flu of the human influenza strain (comprising 17.5%), North American swine (comprising 30.6%), and Eurasian swine (comprising 17.5%). Due to this coinfection with influenza virus from diverse animal species, the viruses were able to interact, mutate, and form new strains that had variable immunity. Although it had originated in pigs, it was able to spread from human to human. When the flu spreads from human-to-human, instead of from animals to humans, there can be further mutations, making it harder to treat because people have no natural immunity. [4][5][6]

Risk Factors

Swine flu was first isolated from pigs in the 1930s by researchers in the United States and was subsequently recognized by pork producers and veterinarians as a cause of flu infections in pigs worldwide, and for the next 60 years, H1N1 was the predominant swine influenza strain. People who are closely associated with pigs have been known to develop an infection, and pigs have also been infected with human flu from these handlers. In the vast majority of cases, cross-species transmission of the virus had remained confined to the specific area and not caused national or global infections in either pigs or humans. Unfortunately, due to the potential for genetic variation in the swine flu virus, there is always a possibility for cross-species transmission with the influenza viruses to occur. Investigators concluded that the "2009 swine flu" strain, which originated in Mexico, was termed novel H1N1 flu since it was mainly found infecting humans and exhibits 2 main surface antigens, hemagglutinin type 1 and neuraminidase type 1. The 8 RNA strands in novel H1N1 flu have 1 strand from human flu strains, 2 derived from avian (bird) strains, and 5 that were derived from swine strains. During the 2009 pandemic, the Centers for Disease and Control and Prevention (CDC) estimated that there were 43 to 89 million cases of swine flu reported during a 1-year span, with 1799 deaths in 178 countries worldwide. [7][8]

The 1918 deadly influenza pandemic caused by H1N1 influenza virus, infected approximately 500 million people around the world and caused the death of roughly fifty to a hundred million people. The H1N1 variant of swine flu is the progeny of the strain that caused the 1918 swine flu pandemic. Although persisting in pigs, the descendant variants of the 1918 virus have also known to infect humans, contributing to the yearly seasonal epidemics of influenza. Direct transmission of the virus from pigs to humans is a rare occurrence, with only 12 documented cases in the United States since 2005. The potential retention of influenza virus strains in swine after these strains have disappeared in the human population, essentially make pigs a reservoir where swine influenza viruses could persist, and later emerge to reinfect humans once their immunity to these strains has waned. [1][9]

More recently in 2015, a mutant strain of H1N1 which caused the global pandemic in 2009, spread across India with over 10,000 reported cases and 774 deaths.

People who have a higher risk of becoming seriously ill if infected include:

  • Children younger than 5 years old
  • Adults older than age 65, younger adults, and children under age 19 who are on long-term aspirin therapy
  • People with compromised immune systems due to diseases such as AIDS
  • Currently gestating females
  • People suffering from chronic diseases such as asthma, heart disease, diabetes mellitus, or neuromuscular disease

Assessment

The history and clinical presentations of H1N1 swine influenza have ranged from mild flu symptoms to severe respiratory symptoms (and possibly death) depending on the age of the patient, co-morbidities, vaccination status, and natural immunity in patients to the virus. According to the CDC, the signs and symptoms in humans infected with the 2009 H1N1 swine flu were similar to those of influenza. These include a fever and chills, cough, sore throat, congested eyes, myalgia, shortness of breath, weight loss, chills, sneezing, headache,  rhinorrhea, coughing, dizziness, abdominal pain, decreased appetite, and fatigue. The 2009 H1N1 strain also showed an increased number of people reporting vomiting and diarrhea as well. Because most of these symptoms are not exclusive to swine flu, a detailed history must also be taken to take into account the differential diagnosis of swine flu if the patient has directly contacted someone with confirmed swine flu or has been in an area that had documented cases of swine flu. Respiratory failure was the most common cause of death in severe cases. Other causes included high fever (causing neurological problems), pneumonia (causing sepsis), dehydration and severe hypotension (from vomiting and diarrhea), electrolyte imbalance associated complications, and kidney failure. More severe cases and fatalities were more likely observed in children younger than 5 years of age and elderly patients older than 60 years.

Other risk factors for severe disease include lung disorders such as chronic obstructive pulmonary disease (COPD), bronchial asthma, pneumonia, currently pregnant women, obesity, patients undergoing immunosuppressive therapy due to cancer or autoimmune disease, and underlying medical issues such as diabetes. Pregnant women acquired the infection during their third trimester were at greater risk for complications.

Evaluation

Influenza A (H1N1) virus infection could be encountered in a wide range of clinical settings and may result in variable pathologic findings. H1N1 should be one of the differential diagnosis in patients who present with unexplained flu-like symptoms or acute pneumonia in an area with known swine flu cases. Routine investigations should be performed for the patient who presents with these symptoms. These usually include hematological, microbiological, biochemical and radiologic tests. A respiratory sample (simple nose or throat swab) is required for a confirmed diagnosis of swine flu. In humans, these tests include the Reverse transcriptase polymerase chain reaction test (RT-PCR), virus isolation test, and assays to detect a 4-fold increase in influenza virus antigens. The routine tests done to detect human influenza viruses, including the rapid test kits, do not always detect zoonotic viruses.

An indication that a novel, possibly zoonotic swine influenza virus could be present, is a detection of the influenza A virus, but not of the hemagglutinins in the seasonal human influenza viruses. The zoonotic influenza virus infections can sometimes be diagnosed retrospectively by serology, but potential cross-reactivity with human influenza viruses can complicate this diagnosis. Another concern is that the neuraminidase (NA) and hemagglutinin (HA) of some swine influenza viruses (the main target of the antibodies) originated from human influenza viruses, to which people could have already been exposed.

State, regional, and national public health laboratories do generally test for the novel influenza viruses.

Medical Management

The initial and best step in management should be to prevent swine flu. Specifically, with prevention of swine flu in swine, prevention of transmission of swine flu from swine-to-humans, and prevention of human-to-human spread.

  1. Prevention of swine flu in swine: Main methods to prevent swine flu in pigs involve facility management (using disinfectants and regulated temperature to control viruses in the environment), herd management (not adding pigs possibly carrying influenza to the herds that have not yet been exposed to the virus), and vaccination. As much of the morbidity and mortality observed with swine flu is due to secondary infection by other pathogens, strategies that solely rely on vaccination may be insufficient.
  2. Prevention of swine to human viral transmission: Because swine can be infected with avian and human strains of H1N1 influenza, they are the primary hosts where antigenic shifts occur that can cause new strains of swine flu. Transmission of the influenza virus from swine to humans is usually seen in people who have a close association with pigs, such as farmers, pork handlers, and veterinarians. These individuals are strongly encouraged to wear face-masks when dealing with the animals to prevent transmission through respiratory droplets. The most important step of prevention is vaccination of the swine. Individuals with increased risk of acquiring swine flu through pigs are those who smoke and do not wear gloves or masks when dealing with infected animals, increasing the risk of possible hand-to-nose, hand-to-eye, or hand-to-mouth transmission.
  3. Prevention of human to human transmission: The main route of swine flu virus spread between humans is exposure to the virus when someone infected sneezes or coughs, and the virus enters one of the potential mucous surfaces, or when a person touched something infected with the virus and subsequently touch their nose, mouth, and surrounding areas. Swine flu is most contagious in the first 5 days of illness in most people, although this may increase in children and the elderly. Current CDC recommendations to prevent the spread of virus include frequent hand washing with soap and water or alcohol-based sanitizers, and also disinfecting household, hospital and public settings by cleaning with a diluted bleach solution. Anyone who resides in an area where the disease is prevalent and suspects an infection or presents with flu-like symptoms, should stay away from work and public transportation and immediately see a doctor.

The best-known prevention method against swine flu is getting the H1N1 swine flu vaccine. In September 2009, the FDA permitted the new swine flu vaccine, and various studies by the National Institute of Health (NIH) showed that a single dose was enough to create sufficient antibodies to protect against the virus within 10 days. The vaccination is contraindicated in people who had a previous severe allergic reaction to the influenza vaccination. Those who are moderate to severely ill, including those with or without a fever, should take the vaccination when they recover or are asymptomatic.

The management for infected patients depends on the severity of symptoms of influenza, mild to moderate influenza can be treated at home with rest, oral hydration and symptomatic treatment with antipyretics like paracetamol, antihistaminic for nasal congestion and rhinitis and NSAIDS or Paracetamol for headaches and body aches. Patients with progressive or severe symptoms should be admitted to hospitals and preferably in intensive care units (ICU) if there are signs suggestive of impending respiratory failure or sepsis or multiorgan dysfunction. Aggressive supportive measures like intravenous (IV) hydration, correction of electrolyte imbalances, antibiotics for concomitant bacterial infections. Patients developing acute respiratory distress syndrome (ARDS) secondary to influenza should be treated with noninvasive or invasive mechanical ventilation. Severe cases of H1N1-induced ARDS have required the use of extracorporeal membrane oxygenation (ECMO).

The antiviral medications: zanamivir, oseltamivir, and peramivir have been documented to help reduce, or possibly prevent, the effects of swine flu if the medication is taken within 48 hours of the onset of symptoms. Known side effects of oseltamivir comprise skin conditions that are occasionally severe and sporadic transient neuropsychiatric events. These possible side effects are the reason the use of oseltamivir is cautioned in the elderly and individuals that have a higher risk of developing these side effects. An allergy to eggs is the only contraindication to zanamivir. Beginning October 1, 2008, the CDC tested 1146 seasonal influenza A (H1N1) collected viruses for resistance to the drugs oseltamivir and zanamivir. It concluded that 99.6% of the samples showed resistance to oseltamivir while none showed resistance to zanamivir. Of the 853 collected samples of the 2009 influenza A (H1N1) virus, only 4% demonstrated resistance to oseltamivir, while none of the 376 samples collected showed resistance to zanamivir.

Pregnant women who contract the H1N1, are at a greater risk of complications because of the body's hormonal changes, physical changes and changes to their immune system to accommodate the growing fetus. For these reasons, the CDC recommends that all pregnant women get vaccinated to prevent the swine influenza virus. Swine influenza in pregnant women can be treated using antiviral medications: oseltamivir and zanamivir (neuraminidase inhibitors). It has been demonstrated that these 2 drugs are most effective when taken within 2 days of becoming sick. [10][11][12]

Nursing Management

  • Check vitals and temperature
  • Isolate the patient
  • Wear mask and gloves
  • Encourage patient to cough and sneeze into a tissue
  • Encourage fluids
  • Provide oxygenation
  • Administer antiviral medications
  • Encourage hand washing
  • Listen to the chest for rales, crackles, wheezing
  • Assess for respiratory distress
  • Use alcohol-based hand gels for hand rinsing
  • Encourage patient to wear a mask

When To Seek Help

  • High fever
  • LOC
  • Altered mental status
  • Dehydrated
  • Respiratory distress
  • Cyanosis
  • Low oxygen saturation
  • Unresponsive

Outcome Identification

  • No fever
  • Able to eat, ambulate and void
  • No cough

Coordination of Care

for best results, a multidisciplinary team should provide for the evaluation and care of patients with Swine flu. The team should be aware of patients at a high risk of becoming seriously ill if infected including you children, the elderly, those immunocompromized, gestating females, and those suffering from chronic debilitating diseases. [Level V]

Health Teaching and Health Promotion

  • Educate patient and family about the flu
  • Encourage patient to get vaccinated
  • Discontinue smoking
  • Drink ample fluids
  • Do not mix with crowds until symptoms disappear
  • Avoid work or school until symptoms resolve
  • Wash hands
  • Wear a mask

Risk Management

Swine flu is very contagious and is easily spread from humans after contact with pigs. The infection rapidly leads to moderate to severe symptoms and deaths are not rare. The key is to prevent the infection in the first place.

For best results, an interprofessional team should provide for the evaluation and care of patients with Swine flu. The team should be aware of patients at a high risk of becoming seriously ill if infected including you children, the elderly, those immunocompromized, gestating females, and those suffering from chronic debilitating diseases.

Discharge Planning

Today, the primary care provider, pharmacist and nurse practitioner should recommend the H1N1 vaccine to children and adults at risk. In addition, all pregnant women should be urged to get vaccinated to prevent the high mortality of the infection. The school nurse should encourage closure of the school even if only one case of H1N1 is identified. Parents should be encouraged to get the children vaccinated and prevent them from interacting with others. In the hospital, the nurses should ensure that the patient is in a single isolation room with airborne precautions in place. Appropriate precautions have to be undertaken to prevent contact with body fluids and aerosols released in the air while coughing. Hand washing should be enforced and only a limited number of healthcare personnel should be allowed to come into contact with the infected person.

Evidence-Based Issues

Only through open communication among members of the interprofessional team can the morbidity and mortality of swine flu be reduced. [13][Level V]


(Click Image to Enlarge)
<p>Electron Microscopic View of H1N1 Influenza Virus Particles

Electron Microscopic View of H1N1 Influenza Virus Particles. Digitally colorized transmission electron microscopic view of H1N1 influenza virus particles


Public Health Image Library, Public Domain, Centers for Disease Control and Prevention
Details

Nurse Editor

Chaddie Doerr

Author

Talha N. Jilani

Author

Radia T. Jamil

Author

Andrew D. Nguyen

Editor:

Abdul H. Siddiqui

Updated:

3/4/2024 12:10:17 AM

Feedback:

Send Us Your Comments

References

[1]

Hackett S, Hill L, Patel J, Ratnaraja N, Ifeyinwa A, Farooqi M, Nusgen U, Debenham P, Gandhi D, Makwana N, Smit E, Welch S. Clinical characteristics of paediatric H1N1 admissions in Birmingham, UK. Lancet (London, England). 2009 Aug 22:374(9690):605. doi: 10.1016/S0140-6736(09)61511-7. Epub     [PubMed PMID: 19700001]

[2]

Cao B, Li XW, Mao Y, Wang J, Lu HZ, Chen YS, Liang ZA, Liang L, Zhang SJ, Zhang B, Gu L, Lu LH, Wang DY, Wang C, National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. The New England journal of medicine. 2009 Dec 24:361(26):2507-17. doi: 10.1056/NEJMoa0906612. Epub 2009 Dec 9     [PubMed PMID: 20007555]

[3]

Kshatriya RM, Khara NV, Ganjiwale J, Lote SD, Patel SN, Paliwal RP. Lessons learnt from the Indian H1N1 (swine flu) epidemic: Predictors of outcome based on epidemiological and clinical profile. Journal of family medicine and primary care. 2018 Nov-Dec:7(6):1506-1509. doi: 10.4103/jfmpc.jfmpc_38_18. Epub     [PubMed PMID: 30613550]

[4]

Mena I, Nelson MI, Quezada-Monroy F, Dutta J, Cortes-Fernández R, Lara-Puente JH, Castro-Peralta F, Cunha LF, Trovão NS, Lozano-Dubernard B, Rambaut A, van Bakel H, García-Sastre A. Origins of the 2009 H1N1 influenza pandemic in swine in Mexico. eLife. 2016 Jun 28:5():. pii: e16777. doi: 10.7554/eLife.16777. Epub 2016 Jun 28     [PubMed PMID: 27350259]

[5]

Lewis NS, Russell CA, Langat P, Anderson TK, Berger K, Bielejec F, Burke DF, Dudas G, Fonville JM, Fouchier RA, Kellam P, Koel BF, Lemey P, Nguyen T, Nuansrichy B, Peiris JM, Saito T, Simon G, Skepner E, Takemae N, ESNIP3 consortium, Webby RJ, Van Reeth K, Brookes SM, Larsen L, Watson SJ, Brown IH, Vincent AL. The global antigenic diversity of swine influenza A viruses. eLife. 2016 Apr 15:5():e12217. doi: 10.7554/eLife.12217. Epub 2016 Apr 15     [PubMed PMID: 27113719]

[6]

Mancera Gracia JC, Van den Hoecke S, Saelens X, Van Reeth K. Effect of serial pig passages on the adaptation of an avian H9N2 influenza virus to swine. PloS one. 2017:12(4):e0175267. doi: 10.1371/journal.pone.0175267. Epub 2017 Apr 6     [PubMed PMID: 28384328]

[7]

Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bulletin of the history of medicine. 2002 Spring:76(1):105-15     [PubMed PMID: 11875246]

[8]

Doshi P. The elusive definition of pandemic influenza. Bulletin of the World Health Organization. 2011 Jul 1:89(7):532-8. doi: 10.2471/BLT.11.086173. Epub     [PubMed PMID: 21734768]

[9]

Lei H, Li Y, Xiao S, Lin CH, Norris SL, Wei D, Hu Z, Ji S. Routes of transmission of influenza A H1N1, SARS CoV, and norovirus in air cabin: Comparative analyses. Indoor air. 2018 May:28(3):394-403. doi: 10.1111/ina.12445. Epub 2018 Jan 6     [PubMed PMID: 29244221]

[10]

Keenliside J. Pandemic influenza A H1N1 in Swine and other animals. Current topics in microbiology and immunology. 2013:370():259-71. doi: 10.1007/82_2012_301. Epub     [PubMed PMID: 23254339]

[11]

Lange E, Kalthoff D, Blohm U, Teifke JP, Breithaupt A, Maresch C, Starick E, Fereidouni S, Hoffmann B, Mettenleiter TC, Beer M, Vahlenkamp TW. Pathogenesis and transmission of the novel swine-origin influenza virus A/H1N1 after experimental infection of pigs. The Journal of general virology. 2009 Sep:90(Pt 9):2119-23. doi: 10.1099/vir.0.014480-0. Epub 2009 Jul 10     [PubMed PMID: 19592456]

[12]

Rassy D, Smith RD. The economic impact of H1N1 on Mexico's tourist and pork sectors. Health economics. 2013 Jul:22(7):824-34. doi: 10.1002/hec.2862. Epub     [PubMed PMID: 23744805]

[13]

Nogales A, Martinez-Sobrido L, Chiem K, Topham DJ, DeDiego ML. Functional Evolution of the 2009 Pandemic H1N1 Influenza Virus NS1 and PA in Humans. Journal of virology. 2018 Oct 1:92(19):. doi: 10.1128/JVI.01206-18. Epub 2018 Sep 12     [PubMed PMID: 30021892]

[14]

Tapia R, García V, Mena J, Bucarey S, Medina RA, Neira V. Infection of novel reassortant H1N2 and H3N2 swine influenza A viruses in the guinea pig model. Veterinary research. 2018 Jul 27:49(1):73. doi: 10.1186/s13567-018-0572-4. Epub 2018 Jul 27     [PubMed PMID: 30053826]

[15]

Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, Smith D, Rimmelzwaan GF, Olsen B, Osterhaus AD. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. Journal of virology. 2005 Mar:79(5):2814-22     [PubMed PMID: 15709000]

[16]

Hirst GK. THE AGGLUTINATION OF RED CELLS BY ALLANTOIC FLUID OF CHICK EMBRYOS INFECTED WITH INFLUENZA VIRUS. Science (New York, N.Y.). 1941 Jul 4:94(2427):22-3     [PubMed PMID: 17777315]

[17]

Zebedee SL, Lamb RA. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. Journal of virology. 1988 Aug:62(8):2762-72     [PubMed PMID: 2455818]

[18]

Herrler G, Rott R, Klenk HD, Müller HP, Shukla AK, Schauer R. The receptor-destroying enzyme of influenza C virus is neuraminate-O-acetylesterase. The EMBO journal. 1985 Jun:4(6):1503-6     [PubMed PMID: 2411539]

[19]

Shope RE. SWINE INFLUENZA : III. FILTRATION EXPERIMENTS AND ETIOLOGY. The Journal of experimental medicine. 1931 Jul 31:54(3):373-85     [PubMed PMID: 19869924]

[20]

Kaplan MM. Relationships between animal and human influenza. Bulletin of the World Health Organization. 1969:41(3):485-6     [PubMed PMID: 5309460]

[21]

. Antigenic shift and drift. Nature. 1980 Feb 7:283(5747):524-5     [PubMed PMID: 7354835]

[22]

Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, Brooks WA, Buchy P, Feikin DR, Fowler KB, Gordon A, Hien NT, Horby P, Huang QS, Katz MA, Krishnan A, Lal R, Montgomery JM, Mølbak K, Pebody R, Presanis AM, Razuri H, Steens A, Tinoco YO, Wallinga J, Yu H, Vong S, Bresee J, Widdowson MA. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. The Lancet. Infectious diseases. 2012 Sep:12(9):687-95. doi: 10.1016/S1473-3099(12)70121-4. Epub 2012 Jun 26     [PubMed PMID: 22738893]

[23]

Van Kerkhove MD, Hirve S, Koukounari A, Mounts AW, H1N1pdm serology working group. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza and other respiratory viruses. 2013 Sep:7(5):872-86. doi: 10.1111/irv.12074. Epub 2013 Jan 21     [PubMed PMID: 23331969]

[24]

Nickol ME, Kindrachuk J. A year of terror and a century of reflection: perspectives on the great influenza pandemic of 1918-1919. BMC infectious diseases. 2019 Feb 6:19(1):117. doi: 10.1186/s12879-019-3750-8. Epub 2019 Feb 6     [PubMed PMID: 30727970]

[25]

Cohen J. Swine flu pandemic. What's old is new: 1918 virus matches 2009 H1N1 strain. Science (New York, N.Y.). 2010 Mar 26:327(5973):1563-4. doi: 10.1126/science.327.5973.1563. Epub     [PubMed PMID: 20339037]

[26]

Scholtissek C, Rohde W, Von Hoyningen V, Rott R. On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology. 1978 Jun 1:87(1):13-20     [PubMed PMID: 664248]

[27]

Li X, Guo L, Liu C, Cheng Y, Kong M, Yang L, Zhuang Z, Liu J, Zou M, Dong X, Su X, Gu Q. Human infection with a novel reassortant Eurasian-avian lineage swine H1N1 virus in northern China. Emerging microbes & infections. 2019:8(1):1535-1545. doi: 10.1080/22221751.2019.1679611. Epub     [PubMed PMID: 31661383]

[28]

Chastagner A, Enouf V, Peroz D, Hervé S, Lucas P, Quéguiner S, Gorin S, Beven V, Behillil S, Leneveu P, Garin E, Blanchard Y, van der Werf S, Simon G. Bidirectional Human-Swine Transmission of Seasonal Influenza A(H1N1)pdm09 Virus in Pig Herd, France, 2018. Emerging infectious diseases. 2019 Oct:25(10):1940-1943. doi: 10.3201/eid2510.190068. Epub     [PubMed PMID: 31538914]

[29]

Scholtissek C, Bürger H, Kistner O, Shortridge KF. The nucleoprotein as a possible major factor in determining host specificity of influenza H3N2 viruses. Virology. 1985 Dec:147(2):287-94     [PubMed PMID: 2416114]

[30]

Sun H, Xiao Y, Liu J, Wang D, Li F, Wang C, Li C, Zhu J, Song J, Sun H, Jiang Z, Liu L, Zhang X, Wei K, Hou D, Pu J, Sun Y, Tong Q, Bi Y, Chang KC, Liu S, Gao GF, Liu J. Prevalent Eurasian avian-like H1N1 swine influenza virus with 2009 pandemic viral genes facilitating human infection. Proceedings of the National Academy of Sciences of the United States of America. 2020 Jul 21:117(29):17204-17210. doi: 10.1073/pnas.1921186117. Epub 2020 Jun 29     [PubMed PMID: 32601207]

[31]

Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, Sugerman DE, Druckenmiller JK, Ritger KA, Chugh R, Jasuja S, Deutscher M, Chen S, Walker JD, Duchin JS, Lett S, Soliva S, Wells EV, Swerdlow D, Uyeki TM, Fiore AE, Olsen SJ, Fry AM, Bridges CB, Finelli L, 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. The New England journal of medicine. 2009 Nov 12:361(20):1935-44. doi: 10.1056/NEJMoa0906695. Epub 2009 Oct 8     [PubMed PMID: 19815859]

[32]

Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annual review of pathology. 2008:3():499-522     [PubMed PMID: 18039138]

[33]

Roberts KL, Shelton H, Stilwell P, Barclay WS. Transmission of a 2009 H1N1 pandemic influenza virus occurs before fever is detected, in the ferret model. PloS one. 2012:7(8):e43303. doi: 10.1371/journal.pone.0043303. Epub 2012 Aug 29     [PubMed PMID: 22952661]

[34]

De Serres G, Rouleau I, Hamelin ME, Quach C, Skowronski D, Flamand L, Boulianne N, Li Y, Carbonneau J, Bourgault A, Couillard M, Charest H, Boivin G. Contagious period for pandemic (H1N1) 2009. Emerging infectious diseases. 2010 May:16(5):783-8. doi: 10.3201/eid1605.091894. Epub     [PubMed PMID: 20409367]

[35]

Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR. Morbidity and mortality weekly report. 2009 Aug 21:58(32):893-6     [PubMed PMID: 19696719]

[36]

Esposito S, Daleno C, Baldanti F, Scala A, Campanini G, Taroni F, Fossali E, Pelucchi C, Principi N. Viral shedding in children infected by pandemic A/H1N1/2009 influenza virus. Virology journal. 2011 Jul 13:8():349. doi: 10.1186/1743-422X-8-349. Epub 2011 Jul 13     [PubMed PMID: 21752272]

[37]

Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, Stelfox T, Bagshaw S, Choong K, Lamontagne F, Turgeon AF, Lapinsky S, Ahern SP, Smith O, Siddiqui F, Jouvet P, Khwaja K, McIntyre L, Menon K, Hutchison J, Hornstein D, Joffe A, Lauzier F, Singh J, Karachi T, Wiebe K, Olafson K, Ramsey C, Sharma S, Dodek P, Meade M, Hall R, Fowler RA, Canadian Critical Care Trials Group H1N1 Collaborative. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009 Nov 4:302(17):1872-9. doi: 10.1001/jama.2009.1496. Epub 2009 Oct 12     [PubMed PMID: 19822627]

[38]

Killip MJ, Fodor E, Randall RE. Influenza virus activation of the interferon system. Virus research. 2015 Nov 2:209():11-22. doi: 10.1016/j.virusres.2015.02.003. Epub 2015 Feb 9     [PubMed PMID: 25678267]

[39]

ANZIC Influenza Investigators, Webb SA, Pettilä V, Seppelt I, Bellomo R, Bailey M, Cooper DJ, Cretikos M, Davies AR, Finfer S, Harrigan PW, Hart GK, Howe B, Iredell JR, McArthur C, Mitchell I, Morrison S, Nichol AD, Paterson DL, Peake S, Richards B, Stephens D, Turner A, Yung M. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. The New England journal of medicine. 2009 Nov 12:361(20):1925-34. doi: 10.1056/NEJMoa0908481. Epub 2009 Oct 8     [PubMed PMID: 19815860]

[40]

Taubenberger JK, Layne SP. Diagnosis of influenza virus: coming to grips with the molecular era. Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology. 2001 Dec:6(4):291-305     [PubMed PMID: 11774194]

[41]

Nin N, Sánchez-Rodríguez C, Ver LS, Cardinal P, Ferruelo A, Soto L, Deicas A, Campos N, Rocha O, Ceraso DH, El-Assar M, Ortín J, Fernández-Segoviano P, Esteban A, Lorente JA. Lung histopathological findings in fatal pandemic influenza A (H1N1). Medicina intensiva. 2012 Jan-Feb:36(1):24-31. doi: 10.1016/j.medin.2011.10.005. Epub 2011 Dec 10     [PubMed PMID: 22154847]

[42]

Morris DE, Cleary DW, Clarke SC. Secondary Bacterial Infections Associated with Influenza Pandemics. Frontiers in microbiology. 2017:8():1041. doi: 10.3389/fmicb.2017.01041. Epub 2017 Jun 23     [PubMed PMID: 28690590]

[43]

Shiley KT, Nadolski G, Mickus T, Fishman NO, Lautenbach E. Differences in the epidemiological characteristics and clinical outcomes of pandemic (H1N1) 2009 influenza, compared with seasonal influenza. Infection control and hospital epidemiology. 2010 Jul:31(7):676-82. doi: 10.1086/653204. Epub     [PubMed PMID: 20500086]

[44]

Carcione D, Giele C, Dowse GK, Mak DB, Goggin L, Kwan K, Williams S, Smith D, Effler P. Comparison of pandemic (H1N1) 2009 and seasonal influenza, Western Australia, 2009. Emerging infectious diseases. 2010 Sep:16(9):1388-95. doi: 10.3201/eid1609.100076. Epub     [PubMed PMID: 20735922]

[45]

Lee N, Chan PK, Lui GC, Wong BC, Sin WW, Choi KW, Wong RY, Lee EL, Yeung AC, Ngai KL, Chan MC, Lai RW, Yu AW, Hui DS. Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? The Journal of infectious diseases. 2011 Jun 15:203(12):1739-47. doi: 10.1093/infdis/jir187. Epub     [PubMed PMID: 21606532]

[46]

Lemaitre M, Carrat F. Comparative age distribution of influenza morbidity and mortality during seasonal influenza epidemics and the 2009 H1N1 pandemic. BMC infectious diseases. 2010 Jun 9:10():162. doi: 10.1186/1471-2334-10-162. Epub 2010 Jun 9     [PubMed PMID: 20534113]

[47]

Yu H, Feng Z, Uyeki TM, Liao Q, Zhou L, Feng L, Ye M, Xiang N, Huai Y, Yuan Y, Jiang H, Zheng Y, Gargiullo P, Peng Z, Feng Y, Zheng J, Xu C, Zhang Y, Shu Y, Gao Z, Yang W, Wang Y. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 Feb 15:52(4):457-65. doi: 10.1093/cid/ciq144. Epub 2011 Jan 10     [PubMed PMID: 21220768]

[48]

Jernigan DB, Lindstrom SL, Johnson JR, Miller JD, Hoelscher M, Humes R, Shively R, Brammer L, Burke SA, Villanueva JM, Balish A, Uyeki T, Mustaquim D, Bishop A, Handsfield JH, Astles R, Xu X, Klimov AI, Cox NJ, Shaw MW. Detecting 2009 pandemic influenza A (H1N1) virus infection: availability of diagnostic testing led to rapid pandemic response. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 Jan 1:52 Suppl 1():S36-43. doi: 10.1093/cid/ciq020. Epub     [PubMed PMID: 21342897]

[49]

Wood JM, Gaines-Das RE, Taylor J, Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine. 1994 Feb:12(2):167-74     [PubMed PMID: 8147099]

[50]

Vasoo S, Stevens J, Singh K. Rapid antigen tests for diagnosis of pandemic (Swine) influenza A/H1N1. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009 Oct 1:49(7):1090-3. doi: 10.1086/644743. Epub     [PubMed PMID: 19725784]

[51]

Salvesen HA, Whitelaw CBA. Current and prospective control strategies of influenza A virus in swine. Porcine health management. 2021 Feb 28:7(1):23. doi: 10.1186/s40813-021-00196-0. Epub 2021 Feb 28     [PubMed PMID: 33648602]

[52]

Mengual-Chuliá B, Alonso-Cordero A, Cano L, Mosquera MDM, de Molina P, Vendrell R, Reyes-Prieto M, Jané M, Torner N, Martínez AI, Vila J, Díez-Domingo J, Marcos MÁ, López-Labrador FX. Whole-Genome Analysis Surveillance of Influenza A Virus Resistance to Polymerase Complex Inhibitors in Eastern Spain from 2016 to 2019. Antimicrobial agents and chemotherapy. 2021 May 18:65(6):. doi: 10.1128/AAC.02718-20. Epub 2021 May 18     [PubMed PMID: 33782005]

[53]

Jeong EK, Bae JE, Kim IS. Inactivation of influenza A virus H1N1 by disinfection process. American journal of infection control. 2010 Jun:38(5):354-60. doi: 10.1016/j.ajic.2010.03.003. Epub 2010 Apr 28     [PubMed PMID: 20430477]

[54]

Yamaya M, Nishimura H, Lusamba Kalonji N, Deng X, Momma H, Shimotai Y, Nagatomi R. Effects of high temperature on pandemic and seasonal human influenza viral replication and infection-induced damage in primary human tracheal epithelial cell cultures. Heliyon. 2019 Feb:5(2):e01149. doi: 10.1016/j.heliyon.2019.e01149. Epub 2019 Feb 5     [PubMed PMID: 30839917]

[55]

Lee JH, Gramer MR, Joo HS. Efficacy of swine influenza A virus vaccines against an H3N2 virus variant. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 2007 Jul:71(3):207-12     [PubMed PMID: 17695596]

[56]

Fablet C, Simon G, Dorenlor V, Eono F, Eveno E, Gorin S, Quéguiner S, Madec F, Rose N. Different herd level factors associated with H1N1 or H1N2 influenza virus infections in fattening pigs. Preventive veterinary medicine. 2013 Nov 1:112(3-4):257-65. doi: 10.1016/j.prevetmed.2013.07.006. Epub 2013 Aug 19     [PubMed PMID: 23968780]

[57]

Ma W, Kahn RE, Richt JA. The pig as a mixing vessel for influenza viruses: Human and veterinary implications. Journal of molecular and genetic medicine : an international journal of biomedical research. 2008 Nov 27:3(1):158-66     [PubMed PMID: 19565018]

[58]

Borkenhagen LK, Wang GL, Simmons RA, Bi ZQ, Lu B, Wang XJ, Wang CX, Chen SH, Song SX, Li M, Zhao T, Wu MN, Park LP, Cao WC, Ma MJ, Gray GC. High Risk of Influenza Virus Infection Among Swine Workers: Examining a Dynamic Cohort in China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 Jul 27:71(3):622-629. doi: 10.1093/cid/ciz865. Epub     [PubMed PMID: 31504322]

[59]

Zhang L, Peng Z, Ou J, Zeng G, Fontaine RE, Liu M, Cui F, Hong R, Zhou H, Huai Y, Chuang SK, Leung YH, Feng Y, Luo Y, Shen T, Zhu BP, Widdowson MA, Yu H. Protection by face masks against influenza A(H1N1)pdm09 virus on trans-Pacific passenger aircraft, 2009. Emerging infectious diseases. 2013:19(9):1403-10. doi: 10.3201/eid1909.121765. Epub     [PubMed PMID: 23968983]

[60]

Zhang N, Li Y. Transmission of Influenza A in a Student Office Based on Realistic Person-to-Person Contact and Surface Touch Behaviour. International journal of environmental research and public health. 2018 Aug 9:15(8):. doi: 10.3390/ijerph15081699. Epub 2018 Aug 9     [PubMed PMID: 30096894]

[61]

Rewar S, Mirdha D, Rewar P. Treatment and Prevention of Pandemic H1N1 Influenza. Annals of global health. 2015 Sep-Oct:81(5):645-53. doi: 10.1016/j.aogh.2015.08.014. Epub     [PubMed PMID: 27036721]

[62]

Borse RH, Shrestha SS, Fiore AE, Atkins CY, Singleton JA, Furlow C, Meltzer MI. Effects of vaccine program against pandemic influenza A(H1N1) virus, United States, 2009-2010. Emerging infectious diseases. 2013 Mar:19(3):439-48. doi: 10.3201/eid1903.120394. Epub     [PubMed PMID: 23622679]

[63]

Centers for Disease Control and Prevention (CDC). Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage - United States, October 2009-January 2010. MMWR. Morbidity and mortality weekly report. 2010 Apr 2:59(12):363-8     [PubMed PMID: 20360670]

[64]

Sukhal S, Sethi J, Ganesh M, Villablanca PA, Malhotra AK, Ramakrishna H. Extracorporeal membrane oxygenation in severe influenza infection with respiratory failure: A systematic review and meta-analysis. Annals of cardiac anaesthesia. 2017 Jan-Mar:20(1):14-21. doi: 10.4103/0971-9784.197820. Epub     [PubMed PMID: 28074789]

[65]

Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000 Feb 23:283(8):1016-24     [PubMed PMID: 10697061]

[66]

Cheer SM, Wagstaff AJ. Zanamivir: an update of its use in influenza. Drugs. 2002:62(1):71-106     [PubMed PMID: 11790157]

[67]

Kohno S, Kida H, Mizuguchi M, Shimada J, S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrobial agents and chemotherapy. 2010 Nov:54(11):4568-74. doi: 10.1128/AAC.00474-10. Epub 2010 Aug 16     [PubMed PMID: 20713668]

[68]

Sharma Y, Horwood C, Hakendorf P, Thompson C. Effectiveness of Oseltamivir in reducing 30-day readmissions and mortality among patients with severe seasonal influenza in Australian hospitalized patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021 Mar:104():232-238. doi: 10.1016/j.ijid.2021.01.011. Epub 2021 Jan 9     [PubMed PMID: 33434667]

[69]

Al-Husban N, Obeidat N, Al-Kuran O, Al Oweidat K, Bakri F. H1N1 Infection in Pregnancy; A Retrospective Study of Feto-Maternal Outcome and Impact of the Timing of Antiviral Therapy. Mediterranean journal of hematology and infectious diseases. 2019:11(1):e2019020. doi: 10.4084/MJHID.2019.020. Epub 2019 Mar 1     [PubMed PMID: 30858958]

[70]

Nordstrom BL, Oh K, Sacks ST, L'Italien GJ. Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study. Antiviral therapy. 2004 Apr:9(2):187-95     [PubMed PMID: 15134180]

[71]

Smith EV, Pynn MC, Blackford S, Leopold DJ. Stevens-Johnson syndrome secondary to oseltamivir (Tamiflu). The British journal of general practice : the journal of the Royal College of General Practitioners. 2010 Feb:60(571):133-4. doi: 10.3399/bjgp10X483292. Epub     [PubMed PMID: 20132714]

[72]

Fang S, Qi L, Zhou N, Li C. Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir: A case report. Medicine. 2018 Sep:97(38):e12497. doi: 10.1097/MD.0000000000012497. Epub     [PubMed PMID: 30235756]

[73]

Lee D, Jo H, Jang Y, Bae S, Agura T, Kang D, Kang M, Kim Y, Cho NH, Kim Y, Kang JS. Alloferon and Zanamivir Show Effective Antiviral Activity against Influenza A Virus (H1N1) Infection In Vitro and In Vivo. International journal of molecular sciences. 2022 Dec 30:24(1):. doi: 10.3390/ijms24010678. Epub 2022 Dec 30     [PubMed PMID: 36614125]

[74]

Dunn CJ, Goa KL. Zanamivir: a review of its use in influenza. Drugs. 1999 Oct:58(4):761-84     [PubMed PMID: 10551442]

[75]

Eiland LS, Eiland EH. Zanamivir for the prevention of influenza in adults and children age 5 years and older. Therapeutics and clinical risk management. 2007 Jun:3(3):461-5     [PubMed PMID: 18488077]

[76]

Freund B, Gravenstein S, Elliott M, Miller I. Zanamivir: a review of clinical safety. Drug safety. 1999 Oct:21(4):267-81     [PubMed PMID: 10514019]

[77]

Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA. 1999 Jul 7:282(1):31-5     [PubMed PMID: 10404908]

[78]

Takemoto Y, Asai T, Ikezoe I, Yano T, Ichikawa M, Miyagawa S, Matsumoto J. Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013. Chemotherapy. 2013:59(5):373-8. doi: 10.1159/000362436. Epub 2014 May 10     [PubMed PMID: 24821568]

[79]

Nakamura S, Miyazaki T, Izumikawa K, Kakeya H, Saisho Y, Yanagihara K, Miyazaki Y, Mukae H, Kohno S. Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study. Open forum infectious diseases. 2017 Summer:4(3):ofx129. doi: 10.1093/ofid/ofx129. Epub 2017 Jun 19     [PubMed PMID: 28761899]

[80]

Komeda T, Ishii S, Itoh Y, Ariyasu Y, Sanekata M, Yoshikawa T, Shimada J. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir. II: a pediatric drug use investigation. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2015 Mar:21(3):194-201. doi: 10.1016/j.jiac.2014.11.009. Epub 2014 Nov 26     [PubMed PMID: 25523716]

[81]

Thorlund K, Awad T, Boivin G, Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC infectious diseases. 2011 May 19:11():134. doi: 10.1186/1471-2334-11-134. Epub 2011 May 19     [PubMed PMID: 21592407]

[82]

Somerville LK, Basile K, Dwyer DE, Kok J. The impact of influenza virus infection in pregnancy. Future microbiology. 2018 Feb:13():263-274. doi: 10.2217/fmb-2017-0096. Epub 2018 Jan 11     [PubMed PMID: 29320882]

[83]

Littauer EQ, Esser ES, Antao OQ, Vassilieva EV, Compans RW, Skountzou I. H1N1 influenza virus infection results in adverse pregnancy outcomes by disrupting tissue-specific hormonal regulation. PLoS pathogens. 2017 Nov:13(11):e1006757. doi: 10.1371/journal.ppat.1006757. Epub 2017 Nov 27     [PubMed PMID: 29176767]

[84]

Creanga AA, Johnson TF, Graitcer SB, Hartman LK, Al-Samarrai T, Schwarz AG, Chu SY, Sackoff JE, Jamieson DJ, Fine AD, Shapiro-Mendoza CK, Jones LE, Uyeki TM, Balter S, Bish CL, Finelli L, Honein MA. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstetrics and gynecology. 2010 Apr:115(4):717-726. doi: 10.1097/AOG.0b013e3181d57947. Epub     [PubMed PMID: 20308830]

[85]

Dunstan HJ, Mill AC, Stephens S, Yates LM, Thomas SH. Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study. BJOG : an international journal of obstetrics and gynaecology. 2014 Jun:121(7):901-6. doi: 10.1111/1471-0528.12640. Epub 2014 Mar 7     [PubMed PMID: 24602087]

[86]

Van Kerkhove MD, Vandemaele KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, Carlino LO, Owen R, Paterson B, Pelletier L, Vachon J, Gonzalez C, Hongjie Y, Zijian F, Chuang SK, Au A, Buda S, Krause G, Haas W, Bonmarin I, Taniguichi K, Nakajima K, Shobayashi T, Takayama Y, Sunagawa T, Heraud JM, Orelle A, Palacios E, van der Sande MA, Wielders CC, Hunt D, Cutter J, Lee VJ, Thomas J, Santa-Olalla P, Sierra-Moros MJ, Hanshaoworakul W, Ungchusak K, Pebody R, Jain S, Mounts AW, WHO Working Group for Risk Factors for Severe H1N1pdm Infection. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS medicine. 2011 Jul:8(7):e1001053. doi: 10.1371/journal.pmed.1001053. Epub 2011 Jul 5     [PubMed PMID: 21750667]

[87]

Nguyen-Van-Tam JS, Openshaw PJ, Hashim A, Gadd EM, Lim WS, Semple MG, Read RC, Taylor BL, Brett SJ, McMenamin J, Enstone JE, Armstrong C, Nicholson KG, Influenza Clinical Information Network (FLU-CIN). Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax. 2010 Jul:65(7):645-51. doi: 10.1136/thx.2010.135210. Epub     [PubMed PMID: 20627925]

[88]

Sertogullarindan B, Ozbay B, Gunini H, Sunnetcioglu A, Arisoy A, Bilgin HM, Mermit Cilingir B, Duran M, Yildiz H, Ekin S, Baran A. Clinical and prognostic features of patients with pandemic 2009 influenza A (H1N1) virus in the intensive care unit. African health sciences. 2011 Jun:11(2):163-70     [PubMed PMID: 21857845]

[89]

Delgado-Rodríguez M, Castilla J, Godoy P, Martín V, Soldevila N, Alonso J, Astray J, Baricot M, Cantón R, Castro A, Gónzález-Candelas F, Mayoral JM, Quintana JM, Pumarola T, Tamames S, Sáez M, Domínguez A, CIBERESP Cases and Controls in Pandemic Influenza Working Group. Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors. The Journal of antimicrobial chemotherapy. 2012 Jul:67(7):1739-45. doi: 10.1093/jac/dks098. Epub 2012 Mar 30     [PubMed PMID: 22467633]

[90]

Bellei NC, Cabeça TK, Carraro E, Goto JM, Cuba GT, Hidalgo SR, Burattini MN. Pandemic H1N1 illness prognosis: evidence from clinical and epidemiological data from the first pandemic wave in São Paulo, Brazil. Clinics (Sao Paulo, Brazil). 2013 Jun:68(6):840-5. doi: 10.6061/clinics/2013(06)19. Epub     [PubMed PMID: 23778481]

[91]

Viasus D, Oteo Revuelta JA, Martínez-Montauti J, Carratalà J. Influenza A(H1N1)pdm09-related pneumonia and other complications. Enfermedades infecciosas y microbiologia clinica. 2012 Oct:30 Suppl 4():43-8. doi: 10.1016/S0213-005X(12)70104-0. Epub     [PubMed PMID: 23116792]

[92]

Davis LE. Neurologic and muscular complications of the 2009 influenza A (H1N1) pandemic. Current neurology and neuroscience reports. 2010 Nov:10(6):476-83. doi: 10.1007/s11910-010-0135-1. Epub     [PubMed PMID: 20697982]

[93]

Luyt CE, Combes A, Becquemin MH, Beigelman-Aubry C, Hatem S, Brun AL, Zraik N, Carrat F, Grenier PA, Richard JM, Mercat A, Brochard L, Brun-Buisson C, Chastre J, REVA Study Group. Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS. Chest. 2012 Sep:142(3):583-592. doi: 10.1378/chest.11-2196. Epub     [PubMed PMID: 22948576]

[94]

Del Rio C, Hernandez-Avila M. Lessons from previous influenza pandemics and from the Mexican response to the current influenza pandemic. Archives of medical research. 2009 Nov:40(8):677-80. doi: 10.1016/j.arcmed.2009.12.005. Epub     [PubMed PMID: 20304256]

[95]

Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2003 Oct 15:37(8):1094-101     [PubMed PMID: 14523774]

[96]

Fell DB, Sprague AE, Liu N, Yasseen AS 3rd, Wen SW, Smith G, Walker MC, Better Outcomes Registry & Network (BORN) Ontario. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. American journal of public health. 2012 Jun:102(6):e33-40. doi: 10.2105/AJPH.2011.300606. Epub 2012 Apr 19     [PubMed PMID: 22515877]

[97]

Jackson C, Vynnycky E, Hawker J, Olowokure B, Mangtani P. School closures and influenza: systematic review of epidemiological studies. BMJ open. 2013:3(2):. doi: 10.1136/bmjopen-2012-002149. Epub 2013 Feb 26     [PubMed PMID: 23447463]

[98]

Cauchemez S, Ferguson NM, Wachtel C, Tegnell A, Saour G, Duncan B, Nicoll A. Closure of schools during an influenza pandemic. The Lancet. Infectious diseases. 2009 Aug:9(8):473-81. doi: 10.1016/S1473-3099(09)70176-8. Epub     [PubMed PMID: 19628172]